{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T18:19:21Z","timestamp":1771611561074,"version":"3.50.1"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The efficacy of the recombinant, live, attenuated, tetravalent dengue vaccine (CYD-TDV) against virologically-confirmed dengue (VCD) has been documented in a phase 3 trial in Latin America (CYD15, NCT01374516). This is a descriptive secondary analysis of the efficacy and safety of CYD-TDV in participants from Colombia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Data from 9740 Colombian participants 9\u201316 years of age who were randomized 2:1 to receive CYD-TDV or placebo were assessed to describe the vaccine efficacy of CYD-TDV against VCD and severe VCD. Estimation was made of the relative risk (RR) for hospitalized VCD cases and severe hospitalized VCD cases after the first dose of CYD-TDV, as well as a description of the incidence of hospitalized dengue from the start of the study and per year of the study until study completion.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>During the active phase of the trial in Colombia, the efficacy of CYD-TDV was 67.5% [95% confidence interval (CI): 58.3\u201374.7] against symptomatic VCD due to any serotype from injection 1 (month 0) to 25 months postinjection 1. Over 6 years, the RR across all 4 serotypes was 0.166 (95% CI: 0.09\u20130.29) in hospitalized VCD patients and 0.154 (95% CI: 0.04\u20130.50) in patients with severe hospitalized VCD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Analysis of the data from Colombia mimics the efficacy observed in CYD15 during the active surveillance follow-up (25 months), but with a sustained beneficial RR for dengue hospitalizations on the subsequent years of follow-up. In Colombia, where seroprevalence has been demonstrated to be high in several regions of the country, CYD-TDV is a useful tool to consider as part of an integrated control strategy against endemic dengue, a disease with a high economic impact on the health system.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000002580","type":"journal-article","created":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T15:12:59Z","timestamp":1581347579000},"page":"e30-e36","source":"Crossref","is-referenced-by-count":6,"title":["Secondary Analysis of the Efficacy and Safety Trial Data of the Tetravalent Dengue Vaccine in Children and Adolescents in Colombia"],"prefix":"10.1097","volume":"39","author":[{"given":"Humberto","family":"Reynales","sequence":"first","affiliation":[{"name":"Centro de Atenci\u00f3n e Investigaci\u00f3n M\u00e9dica - CAIMED, Bogot\u00e1, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Carrasquilla","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Santa Fe de Bogot\u00e1, Bogot\u00e1, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Betzana","family":"Zambrano","sequence":"additional","affiliation":[{"name":"Sanofi Pasteur Global Clinical Sciences, Montevideo, Uruguay"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarita","family":"Cort\u00e9s S","sequence":"additional","affiliation":[{"name":"Sanofi Global Head Medical, Bogot\u00e1, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tifany","family":"Machabert","sequence":"additional","affiliation":[{"name":"Sanofi Pasteur Global Clinical Programs, Marcy L\u2019\u00c9toile, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Jing","sequence":"additional","affiliation":[{"name":"Biostatistics and Programming, Clinical Scientific Operations, Sanofi, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Pallardy","sequence":"additional","affiliation":[{"name":"Sanofi Pasteur Global Clinical Programs, Marcy L\u2019\u00c9toile, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Owen","family":"Haney","sequence":"additional","affiliation":[{"name":"Sanofi Pasteur Global Pharmacovigilance, Swiftwater, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha","family":"Faccini","sequence":"additional","affiliation":[{"name":"Centro de Atenci\u00f3n e Investigaci\u00f3n M\u00e9dica - CAIMED, Bogot\u00e1, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana","family":"Quintero","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Santa Fe de Bogot\u00e1, Bogot\u00e1, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Noriega","sequence":"additional","affiliation":[{"name":"Sanofi Pasteur Global Clinical Sciences, Swiftwater, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"142","DOI":"10.4067\/S0716-10182015000300002","article-title":"[Dengue in Colombia: ten years of database records].","volume":"32","author":"Castrill\u00f3n","year":"2015","journal-title":"Rev Chilena Infectol"},{"key":"R2-20230912","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/tay061","article-title":"Dengue infection in international travellers visiting Bali, Indonesia.","volume":"25","author":"Masyeni","year":"2018","journal-title":"J Travel Med"},{"key":"R3-20230912","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/tax015","article-title":"Imported dengue fever in East London: a 6-year retrospective observational study.","volume":"24","author":"Riddell","year":"2017","journal-title":"J Travel Med"},{"key":"R4-20230912","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taz062","article-title":"Severe dengue in travellers: pathogenesis, risk and clinical management.","volume":"26","author":"Halstead","year":"2019","journal-title":"J Travel Med"},{"key":"R5-20230912","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taw062","article-title":"Evidence-based risk assessment and communication: a new global dengue-risk map for travellers and clinicians.","volume":"23","author":"Jentes","year":"2016","journal-title":"J Travel Med"},{"key":"R12-20230912","doi-asserted-by":"crossref","first-page":"e0003499","DOI":"10.1371\/journal.pntd.0003499","article-title":"Epidemiological trends of dengue disease in Colombia (2000-2011): a systematic review.","volume":"9","author":"Villar","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"R13-20230912","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1016\/j.ijid.2012.11.021","article-title":"Effect of climate variables on dengue incidence in a tropical Caribbean municipality of Colombia, Cerete, 2003-2008.","volume":"17","author":"Mattar","year":"2013","journal-title":"Int J Infect Dis"},{"key":"R15-20230912","first-page":"572","article-title":"Aedes aegypti anti-salivary gland antibody concentration and dengue virus exposure history in healthy individuals living in an endemic area in Colombia.","volume":"35","author":"Londo\u00f1o-Renter\u00eda","year":"2015","journal-title":"Biomedica"},{"key":"R16-20230912","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4269\/ajtmh.13-0663","article-title":"Prospective cohort study with active surveillance for fever in four dengue endemic countries in Latin America.","volume":"93","author":"Dayan","year":"2015","journal-title":"Am J Trop Med Hyg"},{"key":"R17-20230912","doi-asserted-by":"crossref","first-page":"34","DOI":"10.7705\/biomedica.v37i1.3208","article-title":"Seroprevalence of dengue infection in the municipalities of Armenia, Calarc\u00e1, La Tebaida and Montenegro in Quind\u00edo, 2014.","volume":"37","author":"Jim\u00e9nez","year":"2017","journal-title":"Biomedica"},{"key":"R18-20230912","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijid.2019.10.045","article-title":"Prevalence of dengue antibodies in healthy children and adults in different Colombian endemic areas.","volume":"91","author":"Velandia-Romero","year":"2019","journal-title":"Int J Infect Dis"},{"key":"R19-20230912","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.4269\/ajtmh.15-0280","article-title":"The burden of dengue and the financial cost to Colombia, 2010-2012.","volume":"94","author":"Castro Rodr\u00edguez","year":"2016","journal-title":"Am J Trop Med Hyg"},{"key":"R21-20230912","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America.","volume":"372","author":"Villar","year":"2015","journal-title":"N Engl J Med"},{"key":"R22-20230912","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy.","volume":"379","author":"Sridhar","year":"2018","journal-title":"N Engl J Med"},{"key":"R23-20230912","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.2307\/2533444","article-title":"Robust variance estimation for the case-cohort design.","volume":"50","author":"Barlow","year":"1994","journal-title":"Biometrics"},{"key":"R24-20230912","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/biomet\/73.1.1","article-title":"A case-cohort design for epidemiologic cohort studies and disease prevention trials.","volume":"73","author":"Prentice","year":"1986","journal-title":"Biometrika"},{"key":"R26-20230912","first-page":"457","article-title":"Dengue vaccine: WHO position paper \u2013 September 2018.","volume":"93","year":"2018","journal-title":"Wkly Epidemiol Rec"},{"key":"R27-20230912","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1016\/j.vaccine.2018.09.063","article-title":"Dengue vaccine: WHO position paper, september 2018 \u2013 recommendations.","volume":"37","year":"2019","journal-title":"Vaccine"},{"key":"R28-20230912","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijid.2017.02.016","article-title":"Dengue virus serological prevalence and seroconversion rates in children and adults in Medellin, Colombia: implications for vaccine introduction.","volume":"58","author":"Carabali","year":"2017","journal-title":"Int J Infect Dis"},{"key":"R29-20230912","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/trstmh\/try037","article-title":"Dengue seroprevalence: data from the clinical development of a tetravalent dengue vaccine in 14 countries (2005-2014).","volume":"112","author":"L\u2019Azou","year":"2018","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"R30-20230912","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1016\/j.vaccine.2019.07.016","article-title":"Pre-vaccination screening strategies for the use of the CYD-TDV dengue vaccine: a meeting report.","volume":"37","author":"Wilder-Smith","year":"2019","journal-title":"Vaccine"},{"key":"R31-20230912","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1016\/S1473-3099(18)30494-8","article-title":"Deliberations of the Strategic Advisory Group of experts on immunization on the use of CYD-TDV dengue vaccine.","volume":"19","author":"Wilder-Smith","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"R32-20230912","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1473-3099(19)30167-7","article-title":"Sensitivity and negative predictive value for a rapid dengue test.","volume":"19","author":"Flasche","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"R33-20230912","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.cmi.2019.01.002","article-title":"Rapid diagnostic tests for determining dengue serostatus: a systematic review and key informant interviews.","volume":"25","author":"Luo","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"R34-20230912","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taz078","article-title":"Evaluation of rapid diagnostic tests and conventional enzyme-linked immunosorbent assays to determine prior dengue infection.","author":"Bonaparte","year":"2019","journal-title":"J Travel Med"},{"key":"R36-20230912","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/tay057","article-title":"Serostatus-dependent performance of the first licensed dengue vaccine: implications for travellers.","volume":"25","author":"Wilder-Smith","year":"2018","journal-title":"Journal of Travel Medicine"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002580","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T22:34:21Z","timestamp":1694558061000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002580","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}